MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Community-Based Multidisciplinary Program for People with Parkinson Disease: A 2-year comparison

    S. Parveen, T. Passmore, B. Brickell, S. Jackson (Stillwater, USA)

    Objective: The current study reports outcomes from a 2 year-long community-based multidisciplinary program for individuals with Parkinson disease (PD) and their families based in Oklahoma…
  • MDS Virtual Congress 2021

    Parkinson’s Disease Medication Safety in the Inpatient Cohort of a Tertiary Centre

    A. Redmond, G. Richard, M. Penugonda, D. Bradley (Dublin 8, Ireland)

    Objective: Our study aimed to determine the accuracy of initial prescribing on hospital admission and the subsequent timing of administration of Parkinson’s disease (PD) medications…
  • MDS Virtual Congress 2021

    Opicapone in clinical practice in Parkinson’s disease patients with motor fluctuations and complications of therapy at baseline: findings from the OPTIPARK study

    H. Reichmann, A. Lees, M. Fonseca, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)

    Objective: This post-hoc analysis evaluated the effects of opicapone (OPC) treatment in patients with Parkinson’s disease (PD) who experience motor fluctuations and complications of therapy…
  • MDS Virtual Congress 2021

    Opicapone in Parkinson’s Disease German Patients with Motor Fluctuations: Findings from the OPTIPARK Study

    H. Reichmann, A. Lees, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)

    Objective: To evaluate opicapone (OPC) when used in everyday clinical practice conditions to treat Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC proved to…
  • MDS Virtual Congress 2021

    Evaluation of a double-target therapeutic in preclinical models of Parkinson’s disease

    FJ. Sanz, C. Solana-Manrique, E. Masià, MJ. Vicent, N. Paricio (Burjassot, Spain)

    Objective: To evaluate the effectiveness of a candidate compound identified in a high-throughput screening (HTS) assay carried out in a Drosophila model of Parkinson’s disease…
  • MDS Virtual Congress 2021

    Real-world characteristics of advanced Parkinson’s disease patients initiating carbidopa/levodopa enteral suspension

    M. Soileau, I. Malaty, J. Aldred, A. Merola, R. Rodriguez, N. Gupta, I. Sultan, P. Kandukuri, Y. Jalundhwala, O. Ladhani, I. Pan, R. Pahwa (Georgetown, USA)

    Objective: To describe the real-world characteristics of advanced Parkinson’s disease (APD) patients initiating carbidopa/levodopa enteral suspension (CLES) therapy in USA Background: CLES is an FDA…
  • MDS Virtual Congress 2021

    Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Patients With Advanced Parkinson’s Disease

    M. Soileau, F. Pagan, A. Fasano, R. Rodriguez, N. Gupta, A. Xi, M. Kambhampati, A. Murunga, C. Teigland, P. Kandukuri, Y. Jalundhwala, O. Ladhani, M. Siddiqui (Georgetown, USA)

    Objective: To evaluate real-world comparative effectiveness of Carbidopa/Levodopa Enteral Suspension (CLES) versus Deep Brain Stimulation (DBS) initiation on pill burden reduction in patients with Advanced…
  • MDS Virtual Congress 2021

    Limitations of conventional dopaminergic medication in advanced Parkinson’s disease: results from 127 patients treated with Levodopa Carbidopa Intestinal Gel

    J. Szász, V. Constantin, K. Orban-Kiss, L. Bancu, D. Georgescu, J. Szederjesi, M. Ciorba, A. Racz, I. Mihaly, K. Kelemen, S. Szatmari (Targu Mures, Romania)

    Objective: To evaluate the characteristics of the last conventional dopaminergic treatments in a large cohort of patients with advanced Parkinson’s Disease (APD) treated with Levodopa…
  • MDS Virtual Congress 2021

    Pilot study of Phenotype of Antisense-Oligonucleotide-(ASO)-knockdown of Cerebral-Dopamine-Neurotrophic-Factor (CDNF) as Parkinson Disease model : implications for PD and related Dementia Therapeutics

    SS. Chiu, K. Terpstra, RK. Mishra (London, Canada)

    Objective: Our objective is twofold: 1)to examine whether CDNF-ASO paradigm can induce a unique phenotype mimicking PD/PDD/LBW in the rodent species; 2) to evaluate whether…
  • MDS Virtual Congress 2021

    Compensation strategies for gait impairment in Parkinson’s disease: a survey among 4,324 patients

    A. Tosserams, L. Wit, I. Sturkenboom, M. Nijkrake, B. Bloem, J. Nonnekes (Nijmegen, Netherlands)

    Objective: The aim of this study was threefold: (1) to evaluate patients’ awareness and use of various compensation categories for gait impairments in PD; (2)…
  • « Previous Page
  • 1
  • …
  • 747
  • 748
  • 749
  • 750
  • 751
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley